MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of MediciNova (NASDAQ:MNOV) in a note issued to investors on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

MediciNova Stock Performance

Shares of NASDAQ MNOV opened at $1.78 on Monday. The stock has a market capitalization of $87.30 million, a P/E ratio of -10.47 and a beta of 0.75. The stock’s fifty day moving average is $1.62 and its 200 day moving average is $1.47. MediciNova has a 52 week low of $1.12 and a 52 week high of $2.16.

MediciNova (NASDAQ:MNOV) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. Equities research analysts forecast that MediciNova will post -0.23 earnings per share for the current year.

About MediciNova

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.